UI 037
Alternative Names: UI-037Latest Information Update: 27 Aug 2021
At a glance
- Originator Korea United Pharm Inc
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 27 Aug 2021 UI 037 is available for licensing as of 27 Aug 2021. https://www.kup.co.kr/research/innovation_main.htm
- 27 Aug 2021 Phase-I clinical trials in Diabetes mellitus in South Korea (unspecified route), prior to August 2021 (Korea United Pharm pipeline, August 2021)
- 27 Aug 2021 Preclinical trials in Diabetes mellitus in South Korea (unspecified route), prior to August 2021 (Korea United Pharm pipeline, August 2021)